Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
:DXCM
DXCM Stock Chart & Stats
$65.75
$0.53(0.67%)
At close: 4:00 PM EST
$65.75
$0.53(0.67%)
Day’s Range― - ―
52-Week Range$54.11 - $93.25
Previous CloseN/A
Volume488.69K
Average Volume (3M)6.24M
Market Cap
$25.89B
Enterprise Value$26.67B
Total Cash (Recent Filing)$3.32B
Total Debt (Recent Filing)$2.52B
Price to Earnings (P/E)36.9
Beta1.10
Next Earnings
Feb 05, 2026EPS Estimate
0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.61
Shares Outstanding390,016,270
10 Day Avg. Volume5,538,257
30 Day Avg. Volume6,237,215
Financial Highlights & Ratios
PEG Ratio39.32
Price to Book (P/B)14.97
Price to Sales (P/S)7.80
P/FCF Ratio49.89
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue5.91
Enterprise Value/Gross Profit10.01
Enterprise Value/Ebitda21.90
Forecast
1Y Price Target
$85.38Price Target Upside29.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
EPS Forecast (FY)2.06
Revenue Forecast (FY)$4.65B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow And Market ValuationDXCM has the best FCF as a % of net income in Medtech (128%) and is tied with ISRG at the top as a % of revenue (23%).
Growth And Market PositionAnalyst maintains a Buy rating as there is still an expectation of double-digit growth and near-term catalysts.
Medicare Pricing AlignmentThe OIG report is viewed positively for DXCM as it shows Class 2 supplies are priced fairly in line with Medicare expectations.
Bears Say
Guidance And Financial PerformanceThe guide was disappointing with 2025 revenue lifted to reflect Q3 results but GM and adjusted EBITDA guidance lowered as costs related to quality issues continue to impact the P&L.
Market Reaction And Sales Growth ConcernsShares are trading down more than 10% after hours due to lower than hoped for U.S. sales growth and 2026 commentary below the Street.
Product Quality And Competitive ThreatsProduct quality issues and competitive threats will continue to disrupt DXCM’s share gain opportunity.
Dexcom News
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $54.11 and its highest was $93.25 in the past 12 months.
What is Dexcom’s market cap?
Dexcom’s market cap is $25.89B.
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Feb 05, 2026 which is in 49 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Oct 30, 2025. The company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.576 by $0.034.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is 0.65.
How many shares outstanding does Dexcom have?
Dexcom has 390,016,270 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.61 in its last earnings report, beating expectations of $0.576. Following the earnings report the stock price went down -14.633%.
Which hedge fund is a major shareholder of Dexcom?
Currently, no hedge funds are holding shares in DXCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dexcom Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$85.38 (29.86% Upside)
$85.38 (29.86% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.48%
12-Months-Change
Fundamentals
Return on Equity
30.63%
Trailing 12-Months
Asset Growth
18.04%
Trailing 12-Months
Company Description
Dexcom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
DXCM Company Deck
DXCM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
DexCom's earnings call highlighted robust revenue growth and strategic product expansions, particularly in type 2 diabetes CGM coverage, and noted the introduction of innovative products like DexCom Smart Basal. However, challenges in gross margin management and quality issues with the G7 sensor deployment were noted. The sentiment is buoyed by positive financial performance and strategic advancements, despite some operational challenges.View all DXCM earnings summariesDXCM Revenue Breakdown
71.65% U.S.
28.35% Outside of the U.S.
DXCM Stock 12 Month Forecast
Average Price Target
$85.38
▲(29.86% Upside)
Technical Analysis
Ownership Overview
0.48% Insiders
26.92% Mutual Funds
23.49% Other Institutional Investors
16.78% Public Companies and Individual Investors